This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Immunology, Other  • Immunotherapy  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The successful treatment of 6 cases of lentigo maligna (LM) with topical imiquimod was recently reported by Wolf et al.¹ We describe a 78-year-old woman with an extensive recurrent LM (melanoma in situ) that completely regressed after 12 weeks of topical imiquimod therapy. Dermoscopic analysis was useful to confirm the initial diagnosis and to monitor treatment efficacy.

The recently described dermoscopic features of facial LM have proved crucial to differentiate LM from solar lentigo (lentigo senilis), seborrheic keratosis, lichen planus–like keratosis, and pigmented actinic keratosis.² Characteristic dermoscopic features of early-phase LM are asymmetrical pigmented follicular openings, slate-gray dots and globules aggregated around hair follicles, and short brown or black streaks. Disease progression is characterized by the appearance of long and intersected streaks that form rhomboidal structures around the follicles, clearly visible annular-granular structures due to the confluence of dots and globules, and homogeneous areas.² Dermoscopy has been also shown to . . . [Full Text of this Article]

AUTHOR INFORMATION
Tamara Micantonio, MD; Maria Concetta Fargnoli, MD; Ketty Peris, MD

RELATED ARTICLE

Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
Ingrid H. Wolf, Lorenzo Cerroni, Kazuo Kodama, and Helmut Kerl
Arch Dermatol. 2005;141(4):510-514.
ABSTRACT | FULL TEXT